Related Experiment Video
Updated: Aug 24, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Analysis of molecular aberrations in ovarian cancer allows novel target identification
Kwai Wa Cheng1, John P Lahad, Gordon B Mills
1Department of Molecular Therapeutics,The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
The completion of the Human Genome Project and recent advances in functional genomic, proteomic, and high-throughput screening methodologies have provided powerful tools for determining the mechanisms of human diseases, including complex polygenic diseases such as ovarian cancer. These developments may eventually lead to individualized molecular medicine, which is the treatment of patients based on the underlying genetic defects in their tumours and their own genetic makeup. A plethora of novel therapeutic agents that act on specific molecular targets defined by cancer genetics are under development. There is thus a great deal of interest in determining how specific genes and proteins function in cancers, in order to further the understanding of cancer initiation and progression; to aid in identifying biomarkers, therapeutic targets, and determinants of drug responsiveness; and to progress the development of novel antitumour agents.
Insights
Advances in genomics and proteomics enable a deeper understanding of complex diseases like ovarian cancer. This research paves the way for personalized molecular medicine and novel cancer therapies.
Area of Science:
- Genomics
- Proteomics
- Cancer Biology
Background:
- The Human Genome Project and advanced screening methods offer new tools for studying complex diseases.
- Understanding disease mechanisms is crucial for developing targeted treatments.
- Ovarian cancer serves as a model for complex polygenic diseases.
Purpose of the Study:
- To explore the role of functional genomics and proteomics in understanding human diseases.
- To highlight the potential of molecular medicine for personalized cancer treatment.
- To identify new therapeutic targets and biomarkers for ovarian cancer.
Main Methods:
- Utilizing functional genomic and proteomic methodologies.
- Employing high-throughput screening techniques.
- Analyzing genetic defects in tumors and patient genetic makeup.
Main Results:
- Developed powerful tools for determining disease mechanisms.
- Identified potential for individualized molecular medicine.
- Numerous novel therapeutic agents targeting specific molecular cancer targets are in development.
Conclusions:
- Genomic and proteomic advancements are key to understanding cancer initiation and progression.
- This research aids in identifying biomarkers and therapeutic targets.
- Progress in molecular understanding drives the development of novel anti-tumor agents.
